This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Free Online Activities

Evidence for the Use of <span style="font-variant:small-caps;">l</span>-Methylfolate Combined With Antidepressants in MDD

Maurizio Fava, MD; Richard C. Shelton, MD; and John M. Zajecka, MD

Published: August 15, 2011

Article Abstract

Helping patients with major depressive disorder achieve symptom-free remission with antidepressant therapy remains challenging. In this activity, 3 investigators discuss the results of a 2-trial, multicenter, randomized, double-blind, placebo-controlled study of adjunctive l-methylfolate, the bioavailable form of folate, in patients who had inadequately responded to an SSRI. The efficacy of doses of 7.5 mg/d versus 15 mg/d is examined, and the safety and tolerability of l-methylfolate are compared with those of other adjunctive treatments. Different types of folate are explained, and the characteristics of patients who might benefit from adjunctive l-methylfolate are proposed.

See the entire activity.


Related Articles

Volume: 72

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...